Skip to content
Evigrade
CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

Naratriptan stimulates serotonin receptors, including the subtype that constricts intracranial vessels, and in animals it selectively constricts the carotid arteries. Ergotamine constricts arteries on its own. Even in people with no known heart disease it can cause myocardial ischaemia, or rarely infarction, and vasospasm after ergot drugs can be prolonged. Data on naratriptan with ergotamine are limited, but the combination may in theory raise the risk of coronary artery spasm. Naratriptan undergoes little metabolism, spread across many cytochrome P450 enzymes, so significant metabolic interactions are unlikely. The danger of the pair lies in the added vasoconstriction.

Symptoms

After naratriptan, people may feel tingling, numbness, warmth and passing pain, heaviness, pressure or tightness in any part of the body, including the chest and throat, sometimes intense. Within 12 hours of a dose, systolic blood pressure may rise by about 5 mmHg and diastolic by 3 mmHg. In rare cases, triptans have caused hypertensive crisis with acute organ damage. Very rarely, naratriptan causes coronary artery spasm, angina, myocardial infarction and peripheral vascular ischaemia, and rarely ischaemic colitis with abdominal pain and bloody diarrhoea. Ventricular tachycardia and ventricular fibrillation have occurred within hours of triptan use. Vasospasm from ergotamine causes numbness and tingling in the fingers and toes, headache and pain over the heart. In ergotism the limbs turn blue and their pulses disappear.

Management

The naratriptan documents of the Spanish Agency of Medicines and Medical Devices (AEMPS) and the US Food and Drug Administration (FDA) contraindicate the combination. The Spanish summary of product characteristics (SmPC) for ergotamine with caffeine contraindicates triptans as a class and names naratriptan among the triptans that raise the risk of vasospasm (AEMPS). Keep at least 24 hours between naratriptan and an ergotamine product, whichever is taken first (naratriptan SmPC, AEMPS, and label, FDA). If ergotamine has not been enough for an attack, choose an additional migraine drug other than a triptan (ergotamine with caffeine SmPC, AEMPS). Naratriptan is contraindicated in moderate or severe hypertension and in uncontrolled mild hypertension (naratriptan SmPC, AEMPS). Ergotamine is contraindicated in poorly controlled hypertension (ergotamine with caffeine SmPC, AEMPS). Monitor blood pressure during naratriptan treatment (naratriptan label, FDA). If chest pain and tightness spreading to the throat after a naratriptan dose suggest cardiac ischaemia, give no further doses and examine the patient (naratriptan SmPC, AEMPS). If numbness or tingling in the fingers, pain over the heart or other signs of vasospasm appear, stop ergotamine at once and start a peripheral vasodilator. For severe vasospasm, give the peripheral vasodilator intravenously (ergotamine with caffeine SmPC, AEMPS). Stop naratriptan if arrhythmias occur. If signs of spasm in other arteries appear, such as abdominal pain with bloody diarrhoea or white, numb fingers, rule out vasospasm before the next naratriptan dose (naratriptan label, FDA). Taking acute migraine drugs, whether ergotamine, triptans or both, on 10 or more days a month can make headaches more frequent. The overused drugs may then need to be withdrawn (naratriptan label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ergotamine

Other interactions with Naratriptan